newsfilter
← Latest News
Business Wire·

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration - Phase 1a data shows favorable pharmacokinetic (PK) profile of SAT-3247, reinforcing